---
schema_version: "secwatch.filing_event.v1"
accession: "0001789769-26-000018"
form_type: "8-K"
ticker: "TIL"
cik: "0001789769"
company_name: "Instil Bio, Inc."
filed_at: "2026-03-27T23:59:59+00:00"
generated_at: "2026-05-15T08:40:23.453374+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Instil Bio discontinues AXN-2510, pivots to acquisitions; cash $76.3M

## Summary
- Discontinued clinical development of AXN-2510; terminated license with ImmuneOnco.
- Cash, equivalents & marketable securities $76.3M as of Dec 31, 2025, down from $115.1M year-end 2024.
- Management evaluating acquisitions and in-licensing opportunities across therapeutic areas.
- Net loss per share (GAAP) $1.21 for Q4 2025; full year net loss $10.70 per share.
- Cash expected to fund operating plan beyond 2027.

## SEC filing metadata
- accession: 0001789769-26-000018
- form_type: 8-K
- ticker: TIL
- cik: 0001789769
- company_name: Instil Bio, Inc.
- filed_at: 2026-03-27T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1789769/000178976926000018/0001789769-26-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1789769/000178976926000018/til-20260327.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001789769-26-000018
- JSON: https://secwatch.observer/filing/0001789769-26-000018.json
- Plain text: https://secwatch.observer/filing/0001789769-26-000018.txt

## Key facts
- Earnings Releases
  Instil Bio, Inc. reported the fourth quarter and full year ended December 31, 2025 results: net income Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,, EPS Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,.
  - Period: the fourth quarter and full year ended December 31, 2025
  - Net income: Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,
  - EPS: Net loss per share, basic and diluted was $1.21 and $10.70 for the fourth quarter and full year ended December 31, 2025,
  - Result: reported results
  source text: On March 27, 2026, Instil Bio, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the fourth quarter and full year ended December 31, 2025
  evidence_url: https://www.sec.gov/Archives/edgar/data/1789769/000178976926000018/0001789769-26-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.